Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy.
about
Engineering HIV-1-resistant T-cells from short-hairpin RNA-expressing hematopoietic stem/progenitor cells in humanized BLT micePost-transcriptional gene silencing, transcriptional gene silencing and human immunodeficiency virusCCR5 Targeted Cell Therapy for HIV and Prevention of Viral EscapeFoamy virus vectors for HIV gene therapyCombinatorial RNA-based gene therapy for the treatment of HIV/AIDSHematopoietic stem cell engineering at a crossroadsViral quasispecies evolutionEvolutionary analysis of human immunodeficiency virus type 1 therapies based on conditionally replicating vectorsCD4(+) T Cells Modified by the Endoribonuclease MazF Are Safe and Can Persist in SHIV-infected Rhesus MacaquesSurvival of the fittest: positive selection of CD4+ T cells expressing a membrane-bound fusion inhibitor following HIV-1 infectionDevelopment of Hematopoietic Stem Cell Based Gene Therapy for HIV-1 Infection: Considerations for Proof of Concept Studies and Translation to Standard Medical PracticeCurrent progress and challenges in HIV gene therapySelective gene transfection of individual cells in vitro with plasmonic nanobubbles.Minimal-length short hairpin RNAs: the relationship of structure and RNAi activityOptimized lentiviral vectors for HIV gene therapy: multiplexed expression of small RNAs and inclusion of MGMT(P140K) drug resistance geneComputational models of HIV-1 resistance to gene therapy elucidate therapy design principlesSelection of potent non-toxic inhibitory sequences from a randomized HIV-1 specific lentiviral short hairpin RNA library.Emerging nanotechnology approaches for HIV/AIDS treatment and prevention.A Conserved Target Site in HIV-1 Gag RNA is Accessible to Inhibition by Both an HDV Ribozyme and a Short Hairpin RNAEmergence of a complex relationship between HIV-1 and the microRNA pathway.Engraftment and lineage potential of adult hematopoietic stem and progenitor cells is compromised following short-term culture in the presence of an aryl hydrocarbon receptor antagonist.Rev-free HIV-1 gene delivery system for targeting Rev-RRE-Crm1 nucleocytoplasmic RNA transport pathwayRNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma.RNAi and small interfering RNAs in human disease therapeutic applications.Cell-type-specific aptamer and aptamer-small interfering RNA conjugates for targeted human immunodeficiency virus type 1 therapy.Enhanced genetic modification of adult growth factor mobilized peripheral blood hematopoietic stem and progenitor cells with rapamycin.Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5Identification of short hairpin RNA targeting foot-and-mouth disease virus with transgenic bovine fetal epithelium cells.HIV-1 RT-dependent DNAzyme expression inhibits HIV-1 replication without the emergence of escape viruses.Replication-competent lentivirus analysis of clinical grade vector products.RNAi-based therapeutics-current status, challenges and prospectsStem cell-based anti-HIV gene therapy.Engineering and optimization of the miR-106b cluster for ectopic expression of multiplexed anti-HIV RNAs.A single lentiviral vector platform for microRNA-based conditional RNA interference and coordinated transgene expression.Inhibition of HIV-1 infection by a unique short hairpin RNA to chemokine receptor 5 delivered into macrophages through hematopoietic progenitor cell transductionPossibilities for RNA interference in developing hepatitis C virus therapeutics.RNA interference approaches for treatment of HIV-1 infectionHydrogen Peroxide Induce Human Cytomegalovirus Replication through the Activation of p38-MAPK Signaling Pathway.Modification of globin gene expression by RNA targeting strategies.Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge
P2860
Q21133769-3ECA6E38-8678-43F7-9305-FC4D7A06B413Q26797870-F2DD2BEC-9EAE-4808-9BF1-DA4F9875AC54Q26801498-1885248A-E26D-4F18-9297-DE2324B82AEAQ26859020-51E23D41-6D10-4B69-B9D6-71D9F96DF7C9Q26866145-09B6C3F5-A199-41D5-B35B-07351021FC2EQ27001570-7C91D0AE-1FC3-4214-8487-EFD9EC2A625BQ27013917-3BB76C61-3043-4306-989A-EC2273226EB1Q28484825-269248C0-8581-4DDB-A1AF-95B5FE777210Q28656393-E0C3CC94-63D1-4243-B122-BD8DD83038BBQ28749594-C9428802-25EB-4C13-9CB6-230196E3B1C5Q29036869-1358232D-B595-445C-A3D2-22696AB8096DQ29393523-8AE68AED-1D1B-417E-9605-E7F9F2AC37C6Q30466731-98461F4C-94E1-4EDF-8D19-641076018F24Q33572896-3858F3F0-9A8D-4CDC-BDF0-346A47B92819Q33586969-CA45DD08-0101-475C-B404-FCDDD5BEB3D2Q33658642-9F46FC82-A5DE-4DC7-BE1D-A64955E8793FQ33719287-6DF0DC9B-9F0B-427A-86C0-BA988A45BE92Q33819656-749E49B1-05AE-4DCE-B1A5-D49C344DF034Q34001054-EB58E467-E289-46F2-9DEF-F8C8B080B28AQ34025960-1D57619B-38B3-4EF7-9082-6D8850E2CBD6Q34082159-12C1DACC-466E-4B5B-BE69-5C8E8A77CE0EQ34099259-DA778D04-AFD5-4434-92E6-CCCED2115FA4Q34121209-E5C2CB72-9B0E-46AE-AAA4-81599C569F9CQ34204092-3B07365D-6037-4E3C-B695-E3C815CCCC8EQ34232003-167596B9-E4F9-4F31-ACDC-4F230AF55433Q34273081-03CD680E-0F37-4753-AD2A-8C8172812B0CQ34325074-989DB415-4E18-4FBF-A15F-39B59F4F3203Q34384367-6E66D4C2-74B9-4C03-967A-E8D0751A217CQ34513742-3B43678B-7902-485A-8C13-23ADD596FB0FQ34621742-5BB02EEB-20AF-4BDE-8F3F-E74AE4C7773DQ34659612-CA556054-252A-43E4-93F8-5A2A809D581EQ34769333-AE045673-3A89-4EE5-BD9C-C0A276F9AE6AQ34830422-4B41B466-6D50-4512-AA35-BA488BD525AAQ35013068-E244C9F5-51DF-46BD-BD7D-3BDDF68390D3Q35122039-BF278770-ED44-4EB4-8908-0300B939D0FCQ35261143-3E3DF63F-5F68-48BE-81EC-A8D3248B0743Q35652119-CFE551C3-10D4-4F49-AF9B-E0A87CE9D621Q35808633-48EC31C4-0D83-4C54-8957-16983529A2B0Q36427146-9AB82900-84BF-4786-99F1-2818EE19E9A1Q36512567-67F021AE-25AE-4C1C-A22B-B1555ACC5231
P2860
Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Long-term inhibition of HIV-1 ...... ucleolar-localizing TAR decoy.
@en
Long-term inhibition of HIV-1 ...... ucleolar-localizing TAR decoy.
@nl
type
label
Long-term inhibition of HIV-1 ...... ucleolar-localizing TAR decoy.
@en
Long-term inhibition of HIV-1 ...... ucleolar-localizing TAR decoy.
@nl
prefLabel
Long-term inhibition of HIV-1 ...... ucleolar-localizing TAR decoy.
@en
Long-term inhibition of HIV-1 ...... ucleolar-localizing TAR decoy.
@nl
P2093
P1433
P1476
Long-term inhibition of HIV-1 ...... ucleolar-localizing TAR decoy.
@en
P2093
Jiing-Kuan Yee
John J Rossi
Joseph Anderson
Ming-Jie Li
Ramesh Akkina
Shirley Li
P304
P356
10.1016/J.YMTHE.2005.07.524
P577
2005-08-22T00:00:00Z